Oakworth Capital’s Precigen PGEN Stock Holding History

Oakworth Capital’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-300	Closed	-$2K	–	575
2019 Q3	$2K	Hold	300	–	–	﹤0.01%	541
2019 Q2	$2K	Hold	300	–	–	﹤0.01%	588
2019 Q1	$2K	Hold	300	–	–	﹤0.01%	549
2018 Q4	$2K	Hold	300	–	–	﹤0.01%	546
2018 Q3	$5K	Hold	300	–	–	﹤0.01%	523
2018 Q2	$4K	Hold	300	–	–	﹤0.01%	550
2018 Q1	$5K	Buy	+300	New	+$4.29K	﹤0.01%	514

Other funds holding PGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oakworth Capital's PGEN Position: Q4 2019 in Review

Oakworth Capital sold out of Precigen (PGEN) in Q4 2019, closing a stake of 300 shares — an estimated $2K sold.

Oakworth Capital first reported a position in PGEN in Q1 2018 and held it in 7 quarters. The position peaked at $5K in Q3 2018. 167 funds tracked by Wall St. Rank hold PGEN as of Q4 2019.

Oakworth Capital reported no remaining Precigen position as of Q4 2019 after selling out during the quarter.
Oakworth Capital sold 300 Precigen shares in Q4 2019, an estimated $2K.
Oakworth Capital first reported a position in Precigen in Q1 2018 and held it in 7 quarters.
Oakworth Capital's Precigen position peaked at $5K in Q3 2018.
167 funds tracked by Wall St. Rank held Precigen as of Q4 2019.

Based on Oakworth Capital's 13F filing for Q4 2019, filed 31 Jan 2020.